Becotatug vedotin plus sintilimab for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a type of nasopharyngeal cancer called non-keratinizing carcinoma (WHO type II or III).
- Your cancer has spread to certain lymph nodes (stage N2-3 or T4N1) but not to distant parts of the body.
- You have not had prior radiation or chemotherapy for this cancer.
- You are in relatively good health (ECOG score 0 or 1) and have adequate blood counts and organ function.
- You are willing to use effective birth control during treatment and for one year after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug called sintilimab to standard chemoradiotherapy (chemo and radiation) is better than chemoradiotherapy alone for a specific type of nasopharyngeal cancer that has spread to neck lymph nodes. Immunotherapy uses your own immune system to fight cancer, and the hope is that adding it before and after standard treatment can improve outcomes.
This trial tests whether giving the study drug becotatug vedotin after standard radiation and chemotherapy can help prevent nasopharyngeal cancer from coming back in people who are at high risk. It aims to see if this additional treatment improves outcomes without causing too many side effects.
This trial tests whether adding an extra treatment after standard chemoradiation can reduce the chance of nasopharyngeal cancer coming back. The new treatment combines an immunotherapy drug (sintilimab) with a chemotherapy pill (capecitabine) for a year.
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
This trial tests a new drug (BL-B01D1) given alone or with another drug that helps the immune system fight cancer (called a PD-1 inhibitor). It is for people with newly diagnosed, locally advanced nasopharyngeal cancer. The goal is to see if this combination can shrink or control the cancer better.
This study tests a new way to treat nasopharyngeal cancer that has spread, using a special type of radiation plus an immunotherapy drug. It is for people who cannot or choose not to have chemotherapy, and it aims to control the cancer while keeping side effects manageable.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.